Welcome to LookChem.com Sign In|Join Free

CAS

  • or

28004-60-6

Post Buying Request

28004-60-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

28004-60-6 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 28004-60-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,0,0 and 4 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 28004-60:
(7*2)+(6*8)+(5*0)+(4*0)+(3*4)+(2*6)+(1*0)=86
86 % 10 = 6
So 28004-60-6 is a valid CAS Registry Number.
InChI:InChI=1/C9H7N3O2S/c10-9-12-11-8(15-9)5-1-2-6-7(3-5)14-4-13-6/h1-3H,4H2,(H2,10,12)

28004-60-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-(1,3-benzodioxol-5-yl)-1,3,4-thiadiazol-2-amine

1.2 Other means of identification

Product number -
Other names 2-amino-5-(3,4-methylenedioxyphenyl)-1,3,4-thiadiazole

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:28004-60-6 SDS

28004-60-6Relevant articles and documents

Synthesis and pharmacological evaluation of 1,3,4-thiadiazole bearing pyrimidine derivatives as STAT3 inhibitor for treatment of breast cancer

Sravanthi,Kaviarasan,Praveen,Sai Kiran, Pindiprolu S. S.,Pavankumar,Gowramma

, p. 2359 - 2370 (2020)

Novel scaffold of 1,3,4-thiadiazolo-(3,2-α)-pyrimidine-6-carbonitrile derivatives was designed based on SAR of known inhibitors of STAT3 and synthesised using optimized reaction condition. These compounds were subjected to in silico studies using Discovery studio software and evaluated for their anticancer activity. A docking study of the newly synthesized compounds was performed; the results showed good binding mode in the active site of STAT3 enzyme. Among the synthesized compounds, compounds B4 and B5 show binding similar to standard drug static. The cellular evaluation indicates that the anticancer activity of compounds B4, B5 (IC50 = 54.51 ± 2.02?μg/mL and 45.43 ± 1.05?μg/mL, respectively) is active against MDA-MB-232 cell line and compounds B5, B7 (IC50 = 40.21 ± 3.01?μg/mL, 56.77 ± 2.96?μg/mL, respectively) are most active against MCF-7 cell lines. From in vitro result, compound B5 subjected to acute oral toxicity studies by OECD 423 guidelines and in vivo anti-cancer studies carried out using DMBA-induced model.

Synthesis, in silico and in vivo evaluation of novel 1, 3, 4-thiadiazole analogues as novel anticancer agents

Gowramma, Byran,Kalirajan, Rajagopal,Kavi-Arasan, Lakshman,Krishna, Swathi,Mohammed, Manal,Praveen, Thaggikuppe K.

, p. 434 - 444 (2020/04/17)

Background: 1,3,4-thiadiazole is a lead molécule which is versatile for a wide variety of biological activities and in continuation of our interest in establishing some novel heterocyclic compounds for antitumor activity. Objective: The objective of the study was to synthesize series of 5-(1,3-benzodioxol-5-yl)-1,3,4-thiadiazol-2-amine derivative and evaluated for their possible in vitro and in vivo anticancer activity. Method: The synthesis of 2-aminonaphthoxy-1,3,4-thiadiazole and 5-(1,3-benzodioxol-5-yl)-1,3,4-thiadiazol-2-amine as intermediates were carried out by cyclization method. A mixture of thiosemi-carbazide and naphthoxyacetic acid/piperonylic acid and phosphoryl chloride were subjected to cy-clization with phosphorous oxychloride to obtain compound 3. Further compounds 1 and 3 were reacted with different aromatic aldehydes in methanol to form compounds 2a-e and 4a-e. The compounds 2a-e and 4a-e were characterized for the melting points, IR, Proton NMR and Mass spectra. The compounds were further evaluated for their anticancer activity. The docking study was performed using Discovery studio 4.1 (Accelrys) software against DNA-binding domain of STAT3. The compounds were analyzed for the ligand-protein binding interaction(s) by molecular docking into the active site of STAT3β using the CDOCKER protocol of Discovery studio (v4.1) Results: The title compounds were screened for in vitro anticancer on human breastadenocarcinoma cells (MCF-7 and Vero). Compounds 4c, 4d and 2d against MCF 7 and 4d against Vero cell lines were found to be the most active dérivatives with IC50 values of 1.03, 2.81 and 3.45 μg/ml against MCF 7 and 31.81 μg/ml against Vero cell lines, respectively. Conclusion: From the in vivo anticancer studies, it was concluded that the synthesized compounds 4c and 4d displayed anticancer activity comparable to the standard drug, while the rest of the compounds demonstrated mild potency for anticancer studies.

FeCl3-promoted synthesis of 1,3,4-thiadiazoles under combined microwave and ultrasound irradiation in water

Feng, Huangdi,Ying, Xili,Peng, Yanqing,Van Der Eycken, Erik V.,Liu, Chuanduo,Zhao, Shanshan,Song, Gonghua

, p. 681 - 686 (2013/07/26)

An eco-friendly and efficient synthesis of substituted 1,3,4-thiadiazole derivatives has been developed. This aqueous heterogeneous approach proceeds smoothly and quickly under combined microwave and ultrasound irradiation in the presence of FeCl3.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 28004-60-6